Replimune Group, Inc.

NasdaqGS:REPL Stok Raporu

Piyasa değeri: US$813.0m

Replimune Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Replimune Group's earnings have been declining at an average annual rate of -33.8%, while the Biotechs industry saw earnings growing at 19% annually.

Anahtar bilgiler

-33.8%

Kazanç büyüme oranı

-21.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranın/a
Özkaynak getirisi-51.6%
Net Marjn/a
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Replimune: Strong Data In A Highly Differentiated Space

Sep 03

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Aug 16
Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Replimune: Continuing To Justify The Bear Thesis (For Now)

May 22

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Feb 06
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Jan 23

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Dec 25
Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Jul 13
Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

Apr 05
Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Jan 06
A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune secures $200M term loan

Oct 07

Replimune: Recent Developments Strengthen Bull Thesis

Aug 12

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Aug 06
Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune Group GAAP EPS of -$0.78 misses by $0.15

Aug 04

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04
We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16
Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02
Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

May 24
Replimune Group (NASDAQ:REPL) Is In A Strong Position To Grow Its Business

Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic

Apr 30

We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Feb 08
We're Interested To See How Replimune Group (NASDAQ:REPL) Uses Its Cash Hoard To Grow

Replimune Group EPS misses by $0.03

Feb 04

Dosing underway in Replimune's early-stage cancer study with gene therapy

Jan 05

Replimune: Interesting Developer Of Oncolytic Immunotherapies

Dec 06

Replimune Group EPS misses by $0.02

Nov 05

Gelir ve Gider Dağılımı

Replimune Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqGS:REPL Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-22060175
31 Mar 240-21661172
31 Dec 230-21059167
30 Sep 230-19957155
30 Jun 230-18255134
31 Mar 230-17451123
31 Dec 220-15746107
30 Sep 220-1474596
30 Jun 220-1334287
31 Mar 220-1183976
31 Dec 210-1083571
30 Sep 210-1003166
30 Jun 210-912760
31 Mar 210-812454
31 Dec 200-752348
30 Sep 200-702146
30 Jun 200-612040
31 Mar 200-531736
31 Dec 190-431530
30 Sep 190-351225
30 Jun 190-301023
31 Mar 190-31920
31 Dec 180-31919
30 Sep 180-28815
30 Jun 180-26713
31 Mar 180-20611
31 Dec 170-1749

Kaliteli Kazançlar: REPL is currently unprofitable.

Büyüyen Kar Marjı: REPL is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: REPL is unprofitable, and losses have increased over the past 5 years at a rate of 33.8% per year.

Büyüme Hızlandırma: Unable to compare REPL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: REPL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: REPL has a negative Return on Equity (-51.59%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin